Jpmorgan Chase & CO Vigil Neuroscience, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Vigil Neuroscience, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 414 shares of VIGL stock, worth $683. This represents 0.0% of its overall portfolio holdings.
Number of Shares
414
Previous 9,137
95.47%
Holding current value
$683
Previous $36,000
97.22%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding VIGL
# of Institutions
53Shares Held
27.9MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.84MShares$9.63 Million2.45% of portfolio
-
Northpond Ventures, LLC4.21MShares$6.95 Million51.65% of portfolio
-
Siren, L.L.C. New York, NY1.99MShares$3.29 Million0.34% of portfolio
-
Bvf Inc San Francisco, CA1.81MShares$2.99 Million0.2% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.65MShares$2.72 Million1.03% of portfolio
About Vigil Neuroscience, Inc.
- Ticker VIGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,268,600
- Market Cap $46.6M
- Description
- Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...